Drug Type Proteolysis-targeting chimeras (PROTAC) |
Synonyms Ubx 362, Ubx362 |
Target |
Action inhibitors |
Mechanism Bcr-Abl inhibitors(Bcr-Abl tyrosine kinase inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Chronic Myelogenous Leukemia | Preclinical | South Korea | 29 Apr 2025 | |
BCR-ABL Negative Atypical Chronic Myeloid Leukemia | Preclinical | South Korea | 11 Dec 2023 |